GE Healthcare to acquire PAA Laboratories GmbH

18-Aug-2011 - United Kingdom

GE Healthcare announced it has reached an agreement to acquire PAA Laboratories, a developer and supplier of cell culture media for biomedical research and the fast-growing biopharmaceutical and vaccine manufacturing industry.  The acquisition of PAA Laboratories will allow GE Healthcare to expand its offering of products and services for cell biology research and for the discovery and manufacture of biopharmaceuticals including recombinant proteins, antibodies and vaccines. Financial terms were not disclosed.

“The acquisition of PAA Laboratories is a significant step forward for our Life Sciences business and for biopharmaceutical manufacturing globally,” said Kieran Murphy, President and CEO of GE Healthcare Life Sciences.  “GE Healthcare Life Sciences is well known for its expertise in the “downstream” processes of biopharmaceutical manufacturing.  Adding “upstream” capabilities will enable us to provide an end-to-end, fully integrated service to our customers.  We believe that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to reduce cost of entry, deliver higher yields of finished product and reduce time to market.”

The global demand for media, sera and reagents for cell culture is predicted to grow from $2.3 billion in 2009 to an estimated $3.9 billion by 2015*.  The acquisition of PAA Laboratories is consistent with GE's strategy to invest in high-technology, innovative businesses that deliver strong top-line growth and expanded margins.  The acquisition also supports GE healthymagination, GE’s global initiative to reduce cost, increase access and improve the quality of healthcare worldwide.

The acquisition, which is subject to customary closing conditions including regulatory approvals, is expected to close in Q3 2011.

*Source BCC Research “The Dynamic Media, Sera, and Reagent Market in Biotechnology” July 2010

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances